Story behind meldonium-from pharmacology to performance enhancement: a narrative review

被引:32
作者
Schobersberger, Wolfgang [1 ,2 ]
Duennwald, Tobias [1 ,2 ]
Gmeiner, Guenther [3 ]
Blank, Cornelia [1 ,2 ]
机构
[1] UMIT, Inst Sports Med Alpine Med & Hlth Tourism, Hall In Tirol, Austria
[2] Tirol Kliniken GmbH, Innsbruck, Austria
[3] Seibersdorf Labor GmbH, Doping Control Lab, Seibersdorf, Austria
关键词
GAMMA-BUTYROBETAINE HYDROXYLASE; FATTY-ACID OXIDATION; LEFT-VENTRICULAR DYSFUNCTION; L-CARNITINE; MYOCARDIAL-INFARCTION; PROTEIN EXPRESSION; INSULIN-RESISTANCE; NEUROPROTECTIVE PROPERTIES; PARKINSONS-DISEASE; HEALTHY-VOLUNTEERS;
D O I
10.1136/bjsports-2016-096357
中图分类号
G8 [体育];
学科分类号
04 ; 0403 ;
摘要
Recent reports from the World Anti-Doping Agency (WADA) indicate an alarming prevalence in the use of meldonium among elite athletes. Therefore, in January 2016, meldonium was added to WADA's prohibited list after being monitored since 2015. Meldonium has been shown to have beneficial effects in cardiovascular, neurological and metabolic diseases due to its antii-schaemic and cardioprotective properties, which are ascribed mainly to its inhibition of beta-oxidation and its activation of glycolysis. Despite its widespread use, there are only a few clinical studies or clinical trials available. Meldonium is registered in most Baltic countries and is easily accessible through the internet with no serious adverse effects reported by the manufacturer so far. Among athletes, meldonium is used with the purpose of increasing recovery rate or exercise performance. The benefit of taking meldonium in view of performance enhancement in athletes is quite speculative and is discussed without sound scientific evidence. This narrative review provides a detailed overview of the drug meldonium, focusing on the main topics pharmacology and biochemical actions, clinical applications, pharmacokinetics, methods of detection and potential for performance enhancement in athletes.
引用
收藏
页码:22 / +
页数:6
相关论文
共 70 条
[1]   Acylcarnitines: potential implications for skeletal muscle insulin resistance [J].
Aguer, Celine ;
McCoin, Colin S. ;
Knotts, Trina A. ;
Thrush, A. Brianne ;
Ono-Moore, Kikumi ;
McPherson, Ruth ;
Dent, Robert ;
Hwang, Daniel H. ;
Adams, Sean H. ;
Harper, Mary-Ellen .
FASEB JOURNAL, 2015, 29 (01) :336-345
[2]   Effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on myocardial derangements induced by hydrogen peroxide in the isolated perfused rat heart [J].
Akahira, M ;
Hara, A ;
Abiko, Y .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1997, 11 (04) :356-364
[3]   Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans [J].
Anderson, Ethan J. ;
Lustig, Mary E. ;
Boyle, Kristen E. ;
Woodlief, Tracey L. ;
Kane, Daniel A. ;
Lin, Chien-Te ;
Price, Jesse W., III ;
Kang, Li ;
Rabinovitch, Peter S. ;
Szeto, Hazel H. ;
Houmard, Joseph A. ;
Cortright, Ronald N. ;
Wasserman, David H. ;
Neufer, P. Darrell .
JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (03) :573-581
[4]  
[Anonymous], 2021, World anti-doping code: International standard prohibited list
[5]   Pharmaceutical Composition for Improving Physical Working Capacity [J].
Baulin, S. I. ;
Rogacheva, S. M. ;
Afanaseva, S. V. ;
Zabanova, E. V. ;
Karagaycheva, Yu. V. .
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2015, 160 (01) :45-48
[6]   Carnitine congener mildronate protects against stress-and haloperidol-induced impairment in memory and brain protein expression in rats [J].
Beitnere, Ulrika ;
Dzirkale, Zane ;
Isajevs, Sergejs ;
Rumaks, Juris ;
Svirskis, Simons ;
Klusa, Vija .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 745 :76-83
[7]   Mildronate: Cardioprotective action through carnitine-lowering effect [J].
Dambrova, M ;
Liepinsh, E ;
Kalvinsh, I .
TRENDS IN CARDIOVASCULAR MEDICINE, 2002, 12 (06) :275-279
[8]   Pharmacological effects of meldonium: Biochemical mechanisMs and biomarkers of cardiometabolic activity [J].
Dambrova, Maija ;
Makrecka-Kuka, Marina ;
Vilskersts, Reinis ;
Makarova, Elina ;
Kuka, Janis ;
Liepinsh, Edgars .
PHARMACOLOGICAL RESEARCH, 2016, 113 :771-780
[9]  
Dzerve V, 2005, Semin Card, V11, P56
[10]  
Dzerve V., 2010, SEM CARDIOVASC MED, V16, P3